Shang Hai Zheng Quan Bao·2026-01-29 20:26Group 1 - The company expects to achieve total operating revenue of approximately RMB 2.365 billion in 2025, representing a growth of around 134% compared to the previous year [1] - The company anticipates turning a profit in 2025, with a net profit attributable to shareholders of approximately RMB 633 million, an increase of about RMB 1.074 billion compared to the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around RMB 534 million, an increase of approximately RMB 974 million compared to the previous year [1] Group 2 - In 2024, the company reported an operating revenue of RMB 1.009 billion, with a total profit of RMB -453 million and a net profit attributable to shareholders of RMB -441 million [2] - The company experienced significant growth in pharmaceutical revenue due to the approval of new indications for its drug, Acalbrutinib, in April 2025, which contributed to rapid sales growth [3] - Business development (BD) revenue also played a crucial role in the revenue increase, with two BD transactions completed in 2025, including a licensing agreement with Prolium Bioscience Inc. and an authorization agreement with Zenas BioPharma, Inc. [4]